Álvaro Nagib Atallah

Álvaro Nagib Atallah

Auto-generated profile, based on publicly available information

Álvaro Nagib Atallah

Universidade Federal de São Paulo (Unifesp), Brazil

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
CBCamila Torres Bezerra
Camila Torres Bezerra
AGAntonio Jose Grande
Antonio Jose Grande
VGVivianny Kelly Galvão
Vivianny Kelly Galvão
DSDouglas Henrique Marin dos Santos
Douglas Henrique Marin dos Santos
ÁAÁlvaro Nagib Atallah
Álvaro Nagib Atallah
VSValter Silva
Valter Silva
Grading of Recommendations Assessment, Development and Evaluation (GRADE) is a tool for assessing evidence produced in synthesis reports. To present the translation into Portuguese of the GRADE checklist, whose original version is in English, and to describe and explain each topic, in order to provide examples to researchers and professionals who will use the tool. Descriptive study developed at Centro Universitário Tiradentes, Maceió, Alagoas, Brazil. This was a translation of the GRADE checklist, with the addition of the Risk Of Bias In Systematic Reviews (ROBIS) tool in the checklist, with examples of its use. Situations of practical use of the tool were presented in order to facilitate and expand the use of assessment of the quality and strength of evidence among Portuguese speakers. The GRADE checklist is valuable in helping to assess the strength and quality of evidence for synthesis reports for healthcare decision-making.

24 January 2005
Verified
Reference Entry
Closed access
KGKatia Kfg Guenaga
Katia Kfg Guenaga
ÁAÁlvaro N Atallah
Álvaro N Atallah
ACAldemar A Castro
Aldemar A Castro
DMDelcio Matos
Delcio Matos
PWPeer Wille-Jørgensen
Peer Wille-Jørgensen

22 April 2003
Verified
Reference Entry
Closed access
PDF file
KGKf Guenaga
Kf Guenaga
DMD Matos
D Matos
ACAa Castro
Aa Castro
AAAn Atallah
An Atallah
PWP Wille-Jørgensen
P Wille-Jørgensen

16 July 2008
Verified
Reference Entry
Closed access
PDF file
FVFlávia Mr Vital
Flávia Mr Vital
HSHumberto Saconato
Humberto Saconato
MLMagdaline T Ladeira
Magdaline T Ladeira
ASAyan Sen
Ayan Sen
CHClaire A Hawkes
Claire A Hawkes
ÁAÁlvaro N Atallah
Álvaro N Atallah

4 August 2007 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Closed access
PDF file
RDRegina P. El Dib
Regina P. El Dib
ÁAÁlvaro N. Atallah
Álvaro N. Atallah
RARegis Andriolo
Regis Andriolo

4 June 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
INIsrael Júnior Borges do Nascimento
Israel Júnior Borges do Nascimento
Dónal O’MathúnaDónal O’Mathúna
Dónal O’Mathúna
Thilo von GrooteThilo von Groote
Thilo von Groote
HAHebatullah Abdulazeem
Hebatullah Abdulazeem
IWIshanka Weerasekara
Ishanka Weerasekara
MMMilena Soriano Marcolino
Milena Soriano Marcolino
Background: Navigating the rapidly growing body of scientific literature on the SARS-CoV-2 pandemic is challenging, and ongoing critical appraisal of this output is essential. We aimed to summarize and critically appraise systematic reviews of coronavirus disease (COVID-19) in humans that were available at the beginning of the pandemic. Methods: Nine databases (Medline, EMBASE, Cochrane Library, CINAHL, Web of Sciences, PDQ-Evidence, WHO’s Global Research, LILACS, and Epistemonikos) were searched from December 1, 2019, to March 24, 2020. Systematic reviews analyzing primary studies of COVID-19 were included. Two authors independently undertook screening, selection, extraction (data on clinical symptoms, prevalence, pharmacological and non-pharmacological interventions, diagnostic test assessment, laboratory, and radiological findings), and quality assessment (AMSTAR 2). A meta-analysis was performed of the prevalence of clinical outcomes. Results: Eighteen systematic reviews were included; one was empty (did not identify any relevant study). Using AMSTAR 2, confidence in the results of all 18 reviews was rated as “critically low”. Identified symptoms of COVID-19 were (range values of point estimates): fever (82–95%), cough with or without sputum (58–72%), dyspnea (26–59%), myalgia or muscle fatigue (29–51%), sore throat (10–13%), headache (8–12%) and gastrointestinal complaints (5–9%). Severe symptoms were more common in men. Elevated C-reactive protein and lactate dehydrogenase, and slightly elevated aspartate and alanine aminotransferase, were commonly described. Thrombocytopenia and elevated levels of procalcitonin and cardiac troponin I were associated with severe disease. A frequent finding on chest imaging was uni- or bilateral multilobar ground-glass opacity. A single review investigated the impact of medication (chloroquine) but found no verifiable clinical data. All-cause mortality ranged from 0.3 to 13.9%. Conclusions: In this overview of systematic reviews, we analyzed evidence from the first 18 systematic reviews that were published after the emergence of COVID-19. However, confidence in the results of all reviews was “critically low”. Thus, systematic reviews that were published early on in the pandemic were of questionable usefulness. Even during public health emergencies, studies and systematic reviews should adhere to established methodological standards.